HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $80
Author: Benzinga Newsdesk | August 07, 2025 06:38am
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $73 to $80.